Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF + Doxorubicin in Metastatic Leiomyosarcoma
NCT03420014Phase 2Recruiting
- Sponsor
- Philogen
- Start
- Dec 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of onfekafusp alfa in leiomyosarcoma (LMS), sponsored by Philogen. Started Dec 2018; status: recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03420014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420014.